MedlineMDLN +2.79%16 ROE % is 4.69% as of Mar. 2026, which is 68% below its 10-year median of 14.48. GuruFocus rates MDLN with a GF Score™ of 16/100. The stock has 3 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Medline ranks better than 89.61% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Medline's annualized net income for the quarter that ended in Mar. 2026 was $516 Mil. Medline's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $11,005 Mil. Therefore, Medline's annualized ROE % for the quarter that ended in Mar. 2026 was 4.69%.
The historical rank and industry rank for Medline's ROE % or its related term are showing as below:
MDLN'
s ROE % Range Over the Past 10 Years
Min: 8.5 Med: 14.48 Max: 425.45
Current: 17.36
During the past 4 years, Medline's highest ROE % was 425.45%. The lowest was 8.50%. And the median was 14.48%.
MDLN's ROE % is ranked better than 89.61% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs MDLN: 17.36
Medline (NAS:MDLN) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Medline ROE % Related Terms
Medline ROE % Historical Data
* Premium members only.
The historical data trend for Medline's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Medline's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medline ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medline's ROE % distribution charts can be found below:
* The bar in red indicates where Medline's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Medline (MDLN) has a ROE % of 4.69% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Medline and its competitors. This is 68% below median its historical median of 14.48. Over the past decade, Medline's ROE % has ranged from 8.50 to 425.45. According to the industry distribution chart, Medline ranks #83 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 10.4%.
Is Medline's ROE % too high?
Medline's current ROE % of 4.69% is 68% below median its 10-year median of 14.48. Over the past 10 years, this metric has ranged from a low of 8.50 to a high of 425.45. The Medical Devices & Instruments industry median ROE % is 2.42. Medline's value of 4.69% is 93.8% above this industry median. Based on the distribution chart, Medline ranks #83 out of 799 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medline has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Medline's ROE % compare to RMD and WST?
According to the Medical Devices & Instruments industry distribution chart, Medline ranks #83 out of 799 companies for ROE %. This places Medline in the top 10% of its industry — outperforming the majority of peers. The industry median ROE % is 2.42. Medline's value of 4.69% is 93.8% above this benchmark. Historically, Medline's own ROE % has ranged from 8.50 to 425.45 over the past decade. While the company's 10-year median is 14.48 vs. the industry median of 2.42, Medline has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medline's current ROE % of 4.69% is 93.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Medline and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medline's current ROE % is 4.69%, which is 68% below median its own 10-year median of 14.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medline stock overvalued right now?
Medline (MDLN) has a current ROE % of 4.69%. The current ROE % is 4.69%, which is 68% below median its 10-year median of 14.48 and 93.8% above the Medical Devices & Instruments industry median of 2.42. Medline's overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Medline (MDLN), the current ROE % is 4.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medline is the largest provider of medical-surgical products and supply chain solutions in the US. The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families—including front-line care, surgical solutions, and laboratory and diagnostics—as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.
16GF Score
Get the complete analysis for MDLN
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDLN has been successfully added to your 
